New maintenance therapy shows promise in preventing T-Cell cancer relapse after transplant
NCT ID NCT05991973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a low dose of the drug chidamide, given after a donor stem cell transplant, can help prevent T-cell acute lymphoblastic leukemia or T-cell lymphoma from coming back. Forty-four patients aged 14 to 70 who were at high risk of relapse took part. The main goal was to see how long they stayed cancer-free without major side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Zhejiang Medical Colleage Zhejiang University
Hangzhou, Zhejiang, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL
- Two-Drug combo aims to tackle Hard-to-Treat T-Cell lymphoma